WuXi AppTec Reports Steady Revenue Growth Amid Diversified Business Expansion
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its 2024 financial...
HKG: 2359
WuXi XDC Expands MOU with LigaChem to Advance Next-Gen ADC Development
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn...
WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359, OTCMKTS: WUXAY), a leading China-based Contract Development...
WuXi AppTec and WuXi Biologics Weigh Asset Sales in US and Europe Over Biosecure Act Concerns
Reports emerged last week in the Financial Times suggesting that WuXi AppTec (HKG: 2359) and...
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...
Consun Pharmaceutical Gets NMPA Go-Ahead for CKD Drug Clinical Trial
Consun Pharmaceutical Group Ltd (HKG: 1681), a leading Chinese pharmaceutical company, has announced that it...
BIO Surveys Members on China-CDMO Dependence Amid BioSecurity Bill Deliberations
The Biotechnology Innovation Organization (BIO), a prominent US industry trade group, is conducting a survey...
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity”...
WuXi AppTec’s Q1 2024 Revenues Affected by COVID-19 Project Exclusion
China’s leading Contract Research Organization (CRO), WuXi AppTec (HKG: 2359, SHA: 603259), has announced its...
BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec
Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from...
WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer
WuXi AppTec (SHA: 603259, HKG: 2359), a leading Contract Research, Development, and Manufacturing Organization (CRDMO)...
WuXi AppTec Denies Unauthorized IP Transfer Allegations Amidst Strong Financial Performance
WuXi AppTec (SHA: 603259, HKG: 2359), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO)...
WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles
WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results...
US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data
The U.S. Senate’s homeland security committee has voted 11-1 in favor of the Prohibiting Foreign...
WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG:...
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...
WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China
WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...
CORXEL Partners with WuXi STA for Sterile Nasal Spray Production
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...
Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance
The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal...